Try our beta test site
16 studies found for:    Isaac's Syndrome
Show Display Options
RSS Create an RSS feed from your search for:
Isaac's Syndrome
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Inherited Myokymia: A Clinical and Genetic Study of a Family
Condition: A Study of Clinical and Genetic Mutations in a Family of Neuromyotonia, so Called Isaac's Syndrome
Intervention:
2 Active, not recruiting Screening and Natural History: Primary Lateral Sclerosis and Related Disorders
Condition: Primary Lateral Sclerosis
Intervention:
3 Terminated
Has Results
Phase III Acute Coronary Syndrome
Condition: Acute Coronary Syndrome
Interventions: Drug: Apixaban;   Drug: Placebo
4 Completed
Has Results
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Untreated Adult Acute Myeloid Leukemia
Interventions: Drug: Azacitidine;   Drug: Entinostat;   Other: Laboratory Biomarker Analysis
5 Active, not recruiting Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
Conditions: Anemia;   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndrome;   Previously Treated Myelodysplastic Syndrome
Interventions: Biological: Epoetin Alfa;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide
6 Completed A Clinical Study of Intravenous Immunoglobulin
Condition: Immunologic Deficiency Syndromes
Intervention: Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV
7 Unknown  An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
Conditions: Autism;   Autistic Disorder;   Asperger's Disorder;   PDD;   Pervasive Developmental Disorder
Intervention: Drug: Gammaplex 5%
8 Completed Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders
Conditions: Primary Immunodeficiency Disorders;   Immune Thrombocytopenic Purpura (ITP);   Kawasaki Syndrome
Intervention: Biological: Immune Globulin Intravenous (Human), 10%
9 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
10 Completed
Has Results
A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases
Condition: Primary Immunodeficiency Diseases
Intervention: Biological: NewGam
11 Active, not recruiting Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
Conditions: Colon Mucinous Adenocarcinoma;   Colon Signet Ring Cell Adenocarcinoma;   Lynch Syndrome;   Stage IIA Colon Cancer;   Stage IIB Colon Cancer;   Stage IIC Colon Cancer
Interventions: Biological: Bevacizumab;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Oxaliplatin
12 Recruiting Breast Cancer WEight Loss Study (BWEL Study)
Condition: Breast Carcinoma
Interventions: Other: Health Education Program;   Other: Weight Loss Intervention
13 Recruiting Cups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School Dropout
Conditions: Reproductive Health;   Herpesvirus Infection;   HIV Infections;   Woman Abuse;   Quality of Life;   Adolescent Behavior
Interventions: Device: Menstrual Cup;   Other: Cash transfer;   Other: Cups and Cash
14 Active, not recruiting Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Lenalidomide;   Other: Pharmacological Study
15 Active, not recruiting Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Hepatocellular Carcinoma;   Advanced Adult Hepatocellular Carcinoma;   Endometrial Serous Adenocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Lung Carcinoid Tumor;   Malignant Pancreatic Gastrinoma;   Malignant Pancreatic Glucagonoma;   Malignant Pancreatic Insulinoma;   Malignant Pancreatic Somatostatinoma;   Metastatic Digestive System Neuroendocrine Tumor G1;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Surface Papillary Adenocarcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Beta Cell Adenoma;   Pancreatic Delta Cell Adenoma;   Pancreatic G-Cell Adenoma;   Pancreatic Polypeptide Tumor;   Recurrent Adult Liver Carcinoma;   Recurrent Digestive System Neuroendocrine Tumor G1;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Regional Digestive System Neuroendocrine Tumor G1;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIA Uterine Corpus Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIB Uterine Corpus Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IIIC Uterine Corpus Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IVA Uterine Corpus Cancer;   Stage IVB Uterine Corpus Cancer;   Uterine Carcinosarcoma
Interventions: Biological: Bevacizumab;   Drug: Temsirolimus
16 Recruiting A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG
Condition: Primary Immunodeficiency
Interventions: Biological: Immune Globulin (Human) Intravenous;   Biological: Commercial Immune Globulin Intravenous

Study has passed its completion date and status has not been verified in more than two years.